- Home
- FBIO vs IGC Comparison
FBIO vs IGC Comparison
Compare FBIO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- IGC
- Stock Information
- Founded
- FBIO 2006
- IGC 2005
- Country
- FBIO United States
- IGC United States
- Employees
- FBIO N/A
- IGC N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- IGC Health Care
- Exchange
- FBIO Nasdaq
- IGC Nasdaq
- Market Cap
- FBIO 49.1M
- IGC 20.2M
- IPO Year
- FBIO N/A
- IGC N/A
- Fundamental
- Price
- FBIO $1.91
- IGC $0.32
- Analyst Decision
- FBIO Strong Buy
- IGC Strong Buy
- Analyst Count
- FBIO 2
- IGC 2
- Target Price
- FBIO $21.00
- IGC $3.88
- AVG Volume (30 Days)
- FBIO 227.2K
- IGC 242.2K
- Earning Date
- FBIO 08-12-2025
- IGC 08-07-2025
- Dividend Yield
- FBIO N/A
- IGC N/A
- EPS Growth
- FBIO N/A
- IGC N/A
- EPS
- FBIO N/A
- IGC N/A
- Revenue
- FBIO $57,784,000.00
- IGC $1,271,000.00
- Revenue This Year
- FBIO $51.59
- IGC $15.26
- Revenue Next Year
- FBIO $44.74
- IGC $3.41
- P/E Ratio
- FBIO N/A
- IGC N/A
- Revenue Growth
- FBIO N/A
- IGC N/A
- 52 Week Low
- FBIO $1.33
- IGC $0.25
- 52 Week High
- FBIO $2.89
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- FBIO 55.88
- IGC 56.87
- Support Level
- FBIO $1.76
- IGC $0.30
- Resistance Level
- FBIO $1.89
- IGC $0.32
- Average True Range (ATR)
- FBIO 0.10
- IGC 0.01
- MACD
- FBIO -0.00
- IGC 0.00
- Stochastic Oscillator
- FBIO 60.00
- IGC 72.08
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.